The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
The medicines watchdog has revealed that almost 50 patients have been hospitalised “in association with glucagon-like peptide ...
Cedars-Sinai experts believe the study's findings can play a crucial role in developing healthcare policies that promote ...
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid ...
Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23.
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback